Volume | 231 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Genprex Inc | GNPX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
2.37 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
2 | 231 | - | 2.09 - 42.40 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
07:04:02 | formt | 131 | US$ 2.2892 | USD |
Genprex Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
3.52M | 1.49M | - | 0 | -30.86M | -20.77 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Genprex News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GNPX Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.48 | 2.64 | 2.30 | 2.42 | 30,449 | -0.1908 | -7.69% |
1 Month | 2.16 | 2.74 | 2.09 | 2.46 | 34,138 | 0.1292 | 5.98% |
3 Months | 4.08 | 5.41 | 2.09 | 3.41 | 55,378 | -1.79 | -43.89% |
6 Months | 10.396 | 14.40 | 2.09 | 8.47 | 273,099 | -8.11 | -77.98% |
1 Year | 31.408 | 42.40 | 2.09 | 20.48 | 402,255 | -29.12 | -92.71% |
3 Years | 151.60 | 162.80 | 2.09 | 96.98 | 845,197 | -149.31 | -98.49% |
5 Years | 66.00 | 308.80 | 2.09 | 117.64 | 1,275,545 | -63.71 | -96.53% |
Genprex Description
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. |